Summary of Significant Accounting Policies (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 28, 2024	Sep. 30, 2023	Sep. 28, 2024	Sep. 30, 2023	Dec. 30, 2023	Dec. 31, 2022
Summary of Significant Accounting Policies [Line Items]
Financing Receivable, Sale	$ 125,100	$ 110,200	$ 420,700	$ 402,200
Financing Receivable, Significant Sales, Transaction Fees	1,800	1,700	6,300	5,400
Basic:
Net income	$ 16,949	$ 125,026	$ 176,972	$ 563,210
Shares (in shares)	159,200,000	159,727,000	159,609,000	159,894,000
Per Share (in usd per share)	$ 0.11	$ 0.78	$ 1.11	$ 3.52
Effect of dilutive securities: [Abstract]
Add: Option shares in the money and dilutive effect of non-vested stock (in shares)	2,875,000	3,409,000	2,937,000	3,378,000
Less: Pro forma treasury shares (in shares)	(1,084,000)	(711,000)	(1,012,000)	(735,000)
Diluted:
Net Income	$ 16,949	$ 125,026	$ 176,972	$ 563,210
Shares (in shares)	160,991,000	162,425,000	161,534,000	162,537,000
Per Share (in usd per share)	$ 0.11	$ 0.77	$ 1.10	$ 3.47
Antidilutive Securities [Abstract]
Cash and cash equivalents	$ 114,778		$ 114,778		$ 126,502
Restricted cash	39,387		39,387		292
Restricted cash included in other long-term assets	106,775		106,775		137,656
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	$ 260,940	$ 253,531	260,940	$ 253,531	264,450	$ 150,168
Revision of Prior Period, Error Correction, Adjustment
Antidilutive Securities [Abstract]
Net income period adjustments			$ 17,900
Revision of Prior Period, Error Correction, Adjustment | Overstatement
Antidilutive Securities [Abstract]
Inventory adjustments					$ 25,100
Stock Options
Antidilutive Securities [Abstract]
Antidilutive securities excluded from computation of earnings per share (in shares)	0	0	0	0
Non Vested Stock
Antidilutive Securities [Abstract]
Antidilutive securities excluded from computation of earnings per share (in shares)	578,342	382,404	585,511	470,213